Boule Diagnostics AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021
May 06, 2021 at 07:00 am EDT
Share
Boule Diagnostics AB publ announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was SEK 100.6 million compared to SEK 118.4 million a year ago. Operating income was SEK 6.8 million compared to SEK 15.2 million a year ago. Net income was SEK 0.3 million compared to SEK 7.4 million a year ago.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
